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A Ab bs st tr ra ac ct t    Tyrosine kinases are important mediators of the signaling cascade, 
determining key roles in diverse biological processes like growth, 
differentiation, metabolism and apoptosis in response to external and 
internal stimuli. Recent advances have implicated the role of tyrosine kinases 
in the pathophysiology of cancer. Though their activity is tightly regulated in 
normal cells, they may acquire transforming functions due to mutation(s), 
overexpression and autocrine paracrine stimulation, leading to malignancy. 
Constitutive oncogenic activation in cancer cells can be blocked by selective 
tyrosine kinase inhibitors and thus considered as a promising approach for 
innovative genome based therapeutics. The modes of oncogenic activation 
and the different approaches for tyrosine kinase inhibition, like small 
molecule inhibitors, monoclonal antibodies, heat shock proteins, 
immunoconjugates, antisense and peptide drugs are reviewed in light of the 
important molecules. As angiogenesis is a major event in cancer growth and 
proliferation, tyrosine kinase inhibitors as a target for anti-angiogenesis can 
be aptly applied as a new mode of cancer therapy. The review concludes with 
a discussion on the application of modern techniques and knowledge of the 
kinome as means to gear up the tyrosine kinase drug discovery process. 
K Ke ey y   w wo or rd ds s    Tyrosine kinase; Cancer; Oncogenic activation; Inhibitor; Drug discovery 
A Au ut th ho or r   
b bi io og gr ra ap ph hy y   
Anup K. Mukhopadhyay is an Associate Professor of the Department of Biotechnology, 
National Institute of Pharmaceutical Education and Research, Punjab, India-160062.  His 
research interest is in the area of mitochondrial bioenergetics of cancer cell of haemato-
oncologic diseases. His research interest also includes kinetics of electron transfer enzyme 
and reactive oxygen species. 
 
Manash K. Paul is a PhD student of the Department of Biotechnology, National Institute of 
Pharmaceutical Education and Research, Punjab, India-160062. his current research includes 
target enzymes in cancer therapeutics and mitochondrial bioenergetics in cancer leukocyte. 
C Co or rr re es sp po on nd di in ng g   
a ad dd dr re es ss s   
Dr. Anup K. Mukhopadhyay, NIPER Communication No 283. e-mail: 
anupniper@yahoo.co.in or akmukhopadhayay@niper.ac.in  Fax: 91172214692 Tel: 
911722214682 Int. J. Med. Sci. 2004 1(2): 101-115 
 
102 
1.   Introduction 
Multicellular organisms live in a complex milieu where signaling pathways contribute to critical 
links, for their existence. Tyrosine kinases are important mediators of this signal transduction process, 
leading to cell proliferation, differentiation, migration, metabolism and programmed cell death. 
Tyrosine kinases are a family of enzymes, which catalyzes phosphorylation of select tyrosine residues 
in target proteins, using ATP. This covalent post-translational modification is a pivotal component of 
normal cellular communication and maintenance of homeostasis [1,2]. Tyrosine kinases are implicated 
in several steps of neoplastic development and progression.  Tyrosine kinase signaling pathways 
normally prevent deregulated proliferation or contribute to sensitivity towards apoptotic stimuli. These 
signaling pathways are often genetically or epigenetically altered in cancer cells to impart a selection 
advantage to the cancer cells. Thus, it is no wonder that aberrant enhanced signaling emanating from 
tyrosine kinase endows these enzymes a dominating oncoprotein status, resulting in the malfunctioning 
of signaling network [3].  
The discovery that SRC oncogene having a transforming non receptor tyrosine kinase activity  [4], 
and the finding of EGFR, the first receptor tyrosine kinase paved the way to the understanding of the 
role and significance of tyrosine kinase in cancer [5]. With the deciphering of the Human Genome 
Project more than 90 tyrosine kinases have been found out. The more science entangles the intricacies 
of cellular signaling the more we find the involvement of tyrosine kinase in cellular signaling circuits 
that are implicated in cancer development. Tyrosine kinases represent a major portion of all oncoprotein 
that play a transforming role in a plethora of cancers.  Hence the identification and development of 
therapeutic agents for disease states that are linked to abnormal activation of tyrosine kinases due to 
enhanced expression, mutation or autocrine stimulation leading to abnormal downstream oncogenic 
signaling have taken a centre stage as a potent target for cancer therapy  [6,7].     
2.  Biochemical mechanism of action of tyrosine kinase 
Tyrosine kinases are enzymes that selectively phosphorylates tyrosine residue in different 
substrates. Receptor tyrosine kinases are activated by ligand binding to their extracellular domain. 
Ligands are extracellular signal molecules (e.g. EGF, PDGF etc) that induce receptor dimerization 
(except Insulin receptor). Different ligands employ different strategies by which they achieve the stable 
dimeric conformation. One ligand may bind with two receptor molecules to form 1:2 ligand: receptor 
complex e.g. growth hormone and growth hormone receptor, while in other cases two ligands binds 
simultaneously to two receptors 2:2 ligand receptor complex and provides the simplest mechanism of 
receptor dimerization e.g. VEGF and VEGFR. The receptor dimerization is also stabilized by receptor–
receptor interactions. Some ligand receptor is not sufficient for some complex and is stabilized by 
accessory molecules e.g. FGFs are unable to activate FGFR complex and is stabilized by heparin sulfate 
proteoglycans (HSPG). Ligand binding to the extracellular domain stabilizes the formation of active 
dimmers and consequently protein tyrosine kinase activation. 
Structural studies of the catalytic core of several RTKs, supported by biochemical and kinetic 
studies of receptor phosphorylation have provided proof that receptor oligomerization increases the 
local concentration of the RTKs, leading to efficient transphosphorylation of tyrosine residues in the 
activation loop of the catalytic domain. Upon tyrosine phosphorylation the activation loop adopts an 
open conformation that gives access to ATP and substrates and makes ATP transfer from Mg-ATP to 
tyrosine residue on the receptor itself and on cellular proteins involved in signal transduction. 
The ATP binding intracellular catalytic domain that catalyzes receptor autophosphorylation 
displays the highest level of conservation between the RTKs. The ATP binding site serves as a docking 
site for specific binding of cytoplasmic signaling proteins containing Src homology-2 (SH2) and protein 
tyrosine binding (PTB) domains. These proteins in turn recruit additional effector molecules having 
SH2, SH3, PTB and Pleckstrin homology (PH) domain. This results in the assembly of signaling 
complexes to the activated receptor and the membrane and subsequent activation of a cascade of 
intracellular biochemical signals, which leads to the activation or repression of various subsets of genes 
and thus defines the biological response to signals. During these processes, receptors migrate within the 
plasma membrane and are internalized through clathrin-coated invagination, which eventually seal off 
and forms an endocytic vesicle. The endocytic vesicles fuse with the lysosomes and in the process the Int. J. Med. Sci. 2004 1(2): 101-115 
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receptor and ligand may be degraded by the lysosomal enzymes. The receptors are also recycled in 
some cases. During the whole process of receptor internalization the ligand receptor complex is 
dissociated and this results in the termination of the signaling reaction.  
Figure 1. Schematic representation of the mode of action of tyrosine kinase. PK represents protein 
kinase and PP stands for protein phosphatase. 
 
 
 
3.  Classification 
Tyrosine kinases are primarily classified as receptor tyrosine kinase (RTK) e.g. EGFR, PDGFR, 
FGFR and the IR and non-receptor tyrosine kinase (NRTK) e.g. SRC, ABL, FAK and Janus kinase. The 
receptor tyrosine kinases are not only cell surface transmembrane receptors, but are also enzymes 
having kinase activity. The structural organization of the receptor tyrosine kinase exhibits a 
multidomain extracellular ligand for conveying ligand specificity, a single pass transmembrane 
hydrophobic helix and a cytoplasmic portion containing a tyrosine kinase domain. The kinase domain 
has regulatory sequence both on the N and C terminal end [2,8]. 
NRTK are cytoplasmic proteins, exhibiting considerable structural variability. The NRTK have a 
kinase domain and often possess several additional signaling or protein-protein interacting domains 
such as SH2, SH3 and the PH domain [9]. The tyrosine kinase domain spans approximately 300 
residues and consists of an N terminal lobe comprising of a 5 stranded β sheet and one α helix, while 
the C terminal domain is a large cytoplasmic domain that is mainly α helical. ATP binds in the cleft in 
between the two lobes and the tyrosine containing sequence of the protein substrate interacts with the 
residues of the C terminal lobe. RTK are activated by ligand binding to the extracellular domain 
followed by dimerization of receptors, facilitating trans-phosphorylation in the cytoplasmic domain 
whereas the activation mechanism of NRTK is more complex, involving heterologous protein-protein 
interaction to enable transphosphorylation  [10]. 
 
Figure 2. Mechanism of action of tyrosine kinase. 1. Receptor expression at membrane claveola 2. 
Ligand binding 3. Hetero/homodimerization leading to tyrosine kinase activation and tyrosine 
transphosphorylation 4. Signal transduction 5. Receptor internalization 6. Receptor degradation or re-
expression. 
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4.  Oncogenic activation of tyrosine kinase  
Normally the level of cellular tyrosine kinase phosphorylation is tightly controlled by the 
antagonizing effect of tyrosine kinase and tyrosine phosphatases. There are several mechanisms by 
which tyrosine kinase might acquire transforming functions, but the ultimate result is the constitutive 
activation of normally controlled pathways leading to the activation of other signaling proteins and 
secondary messengers which serves to hamper the regulatory functions in cellular responses like cell 
division, growth and cell death [11]. Constitutive activation of tyrosine kinase may occur by several 
mechanisms. 
4.1.  Activation by mutation  
An important mechanism leading to tyrosine kinase deregulation is mutation. Mutations within the 
extracellular domain e.g. EGFRv III mutant lacks amino acid 6-273 which gives rise to receptor 
tyrosine kinase constitutive activity, that leads to cell proliferation in the absence of ligand in 
glioblastomas, ovarian tumors and non small cell lung carcinoma [12]. Point mutations either in the 
extracellular domain of the FGFR 3 results in an unpaired cysteine residue allowing abnormal receptor 
dimerization through intermolecular disulfide bonding, or in the activation loop of kinase domain were 
identified in multiple myeloma. Somatic mutations in the EGFR 2 and 3 have been associated with 
human bladder and cervical carcinomas. Breakpoints of abnormal chromosomal translocation are also 
an important source of mutation  [13]. 
4.1.1.  BCR-ABL and human leukemia 
CML is a chronic myelodysplastic hematopoietic stem cell disorder syndrome (95% of the CML) 
resulting from a reciprocal translocation between chromosome-9 and chromosome-22, the Philadelphia 
chromosome. Break point cluster region (BCR) sequences of chromosome-22 on translocation 
juxtaposes with the c-ABL tyrosine kinase of chromosome-9. The fusion gene produces a 210 KDa 
mutant protein in which the first exon of c-ABL has been replaced by BCR sequences, encoding either 
927 or 902 amino acid. Another BCR-ABL fusion protein of 185 KDa containing BCR sequences from 
exon 1fused to exon 2-11 of c-ABL, is found in 10% of adult ALL patients. The BCR-ABL chimeric 
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gene product has a tyrosine kinase activity several fold higher than it’s normal counterpart and 
correlates with the disease phenotype  [14,15,16,17,18]. 
4.1.2.  TEL-ABL and human leukemia 
TEL-ABL tyrosine kinase like ABL-BCR is constitutively phosphorylated due to reciprocal 
translocation t(9,12) in case of ALL and with a complex karyotype t(9,12,14) in patients with CML. 
TEL which is a putative transcription factor is fused in-frame with exon-2 of the ABL proto-oncogene, 
producing a fusion protein product with elevated tyrosine kinase activity  [14,19]. Other important 
translocations include t(5,12) in CMML producing TEL-PDGF receptor. The helix-loop-helix motif of 
TEL is believed to induce homodimerization and kinase activation of the TEL-ABL and TEL-PDGFRβ 
fusion proteins. NPM-ALK fusion products t(2,5) is constitutively activated in Anaplastic large cell 
lymphoma  [20,21]. 
4.2. Autocrine-Paracrine  loops 
Autocrine-paracrine stimulation serves as an important mechanism for the constitutive activation 
of tyrosine kinase specially receptor tyrosine kinases. This activation loop is stimulated when a receptor 
tyrosine kinase is abnormally expressed or overexpressed in presence of it’s associated ligand or when 
there is an overexpression of the ligand in presence of it’s cognate receptor. A role of autocrine-
paracrine stimulation has been immanent in a variety of human cancers. Burning examples are being 
provided by EGFR, PDGFR and IGF receptors and their associated ligands [22]. 
4.2.1.  EGFR in autocrine paracrine loops 
Strong associations have been studied among the expression of EGFR and it’s primary ligand EGF 
and TGFα in many human cancers including non small cell lung cancer [22], bladder cancer, breast 
cancer and glioblastoma multiforme. Increased expression of EGFR is reported in 40-80% of non small 
cell lung cancer and is also overexpressed in 50% of primary lung cancer  [15]. TGFα another ligand of 
EGFR is also involved in autocrine paracrine growth loops in 20-40% of lung cancer [23]. EGFR 
overexpression of wild type or mutated forms is documented in 40% of cases of glioblastoma 
multiforme [24] and 40%-50 % of bladder cancer patient  [25]. 
4.2.2.  PDGFR in Autocrine paracrine Loop 
Concurrent expression of PDGFR and it’s cognate ligand PDGF-A and PDGF-B has been 
observed in most astrocytic brain tumors and gliomas  [26]. 
4.2.3. Insulin like growth factor receptors in Autocrine growth loop 
Coexpression of IGFR and its ligand IGF I and IGF II is reported in the pathogenesis of breast 
cancer, prostrate cancer and small cell lung cancer [27]. Elevated IGF-I R autophosphorylation and 
kinase activity has been reported in breast cancer [28]. Elevated prostrate cancer risk is also correlated 
with elevated plasma IGF-I levels [29]. Hence a strong association of autocrine paracrine loops has 
been implicated in the pathogenesis of several cancers. Int. J. Med. Sci. 2004 1(2): 101-115 
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Figure 3. Schematic view of different mechanisms leading to the constitutive activation of tyrosine    
kinase. 
 
 
 
5.  Tyrosine kinases as targets for anticancer agents 
The role of tyrosine kinases in cancer molecular pathogenesis is immense and recently kinases 
have come in vogue as potential anticancer drug targets, as a result a couple of anticancer drugs are in 
the market. The complexity and the number of tyrosine kinases have greatly increased with the 
sequencing effort of the Human Genome Project, thus providing more opportunities for drug discovery. 
Recent understanding of the molecular pathophysiology of cancer have highlighted that many tyrosine 
kinases are found upstream or downstream of epidemiologically relevant oncogenes or tumor 
suppressor, in particular the receptor tyrosine kinases  [30]. 
5.1.  Site of targeting 
Cancer research got a boom with the declaration by the US president Richard Nixon in The 
National Cancer Act (1971). By the late 1980 there were evidence of low molecular weight tyrosine 
kinase inhibitors. Inhibiting the activity of tyrosine kinases by low molecular weight compounds 
capable of interfering with either ligand binding (in the case of receptor tyrosine kinases)  [31] or with 
protein substrate (in case of non receptor tyrosine kinase) has proved to be difficult [32]. Although the 
bisubstrate inhibitor approach offered promise, but with very little practical progress. Approaches to 
generate non-competitive or allosteric inhibitors have also failed. The ATP competitive inhibitors 
appear to be the target of choice  [33]. 
5.2.  The ATP binding site 
ATP binds within a deep cleft formed between the two lobes of the tyrosine kinase domain. 
Though the ATP binding site is highly conserved the architecture in the regions proximal to the ATP 
binding site does afford some key diversity for designing new drug and has potential application in drug 
discovery. 
The ATP binding sites have the following features- 
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a) Adenine region – contains two key Hydrogen bonds formed by the interaction of N-1 and N-6 
amino group of the adenine ring. Many potent inhibitors use one of these Hydrogen bonds.            
b) Sugar region – a hydrophilic region, except a few e.g. EGFR. Hydrophobic pocket – though not 
used by ATP but plays an important role in inhibitor selectivity. 
c) Hydrophobic channel – not used by ATP and may be exploited for inhibitor specificity. 
d) Phosphate binding region – can be used for improving inhibitor selectivity [34]. 
 
Figure 4. Model of the ATP-binding site of protein kinases. ATP is depicted in red, Sug1, Hyp1 & 
Hyc1 are residues lining the sugar region, hydrophobic pocket (Hyp), hydrophobic channel (Huc) and 
hinge region (Hin) respectively (redrawn) [34]. 
 
 
 
5.3. Small  molecule  inhibitor 
Tyrosine kinase forms a significant share of all oncoproteins thus they take centre stage as possible 
targets for cancer therapy. Hence low molecular weight tyrosine phosphorylation inhibitors 
(tyrphostins) have been proposed to be prospective anti-proliferating agents. By late 1980s it was 
proved that low molecular weight EGFR inhibitors could block EGF dependent cell proliferation [35]. 
Within a short time reports concerning effective tyrosine kinase inhibitors was the key promising 
development in anticancer development. With further research in the following years it was quite clear 
that neglected kinase targets against the biases have come into vogue [36]. Most of the tyrosine kinase 
inhibitors generated since have been ATP mimics. Interestingly many tyrphostins that possess one 
aromatic ring are substrate mimics [37]. These substrate mimics can be interestingly converted into 
ATP mimics once the nitrogen of the characteristic benzene malonitrile is incorporated into the second 
ring. Compounds that are found to be ATP mimics possess at least two aromatic rings. The ATP 
binding site though evolutionarily conserved can be selectively targeted by taking advantage of the 
minor difference in the kinase domain. The minor difference leads to changes in hydrogen bonding and 
hydrophobic interactions resulting in differences of affinity  [38].  
Of all the tyrosine kinase inhibitors the most successful are Gleevec, Iressa and Tarceva. The novel 
anticancer drug Gleevec/ Glivec/ Imatinib mesylate (Novartis STI571) is a success for CML and c-kit 
positive metastatic GIST. Gleevec selectively and effectively inhibits the kinase activity of BCR-ABL 
fusion protein, which is responsible for the constitutive proliferative signaling. It also inhibits TEL-
ABL and TEL-PDGFR fusion proteins. STI571 remains bound to the ATP binding cleft of the 
unphospholrylated (activation loop) Abl, thus establishing extensive contacts with residues lining the 
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cleft and with peptide segments just outside the cleft. A large change in conformation of the nucleotide 
binding domain is accompanied with the binding of the drug. The binding of STI571 prevents ATP to 
access the ATP binding cleft and thus inhibits subsequent tyrosine phosphorylation of the substrate 
[34,36,39]. Iressa is a selective inhibitor of EGF receptor tyrosine kinase in non small cell lung cancer 
and squamous cell carcinoma  [40]. 
The downstream target of PI3K pathway, mTOR (non receptor tyrosine kinase) responsible for 
abnormal cellular growth and proliferation in glioblastoma and renal cancer is inhibited by rapamycin 
and CCI779. These two compounds are currently in phase II studies  [41].  
Figure 5. Structure of some of the important protein kinase inhibitors. 
 
 
5.4. Monoclonal  antibody 
The extracellular domain of the receptor tyrosine kinase provides an excellent target for 
monoclonal antibodies. With the advancement of genomics, design, selection and production of 
therapeutic monoclonal antibodies has become much more easier.  The revolution in antibody 
technology now allows us to produce humanized, human chimeric or bispecific antibody for targeted 
cancer therapy [31,42].  
The EGFR family of receptor tyrosine kinase comprises of four members – the EGFR/ Erb B1, 
HER-2/ Erb B2, HER-3/ Erb B3 and HER-4/ Erb B4. Members of the EGFR family are involved in 
some complex biological signal transduction network. Both EGFR and HER-2/ neu are amplified in 
tumor samples of breast, lung and colorectal tissues. Their overexpression leads to elevated MAP 
kinase and PI3 kinase recruitment and subsequent suppression of apoptosis, deregulation of cell cycle 
and proliferation. 
Based on the discovery of the importance of HER-2 gene amplification in breast cancer Herceptin 
(Transtuzumab) was developed by Genetech in 1988 and is one of the best examples of targetted next 
generation anticancer therapeutic for cancer. Tyrosine kinases are key regulators of cell survival and 
proliferation in breast cancer [42,43]. The orphan receptor tyrosine kinase HER2 gene is amplified in 
breast cancer and acts as a major signaling partner for other EGFR family members leading to 
proliferation, differentiation, antiapoptosis [44] and tumor progression [45]. Herceptin was the first 
genome based targeted anticancer therapeutic, approved by FDA in 1998. Binding of Herceptin to HER 
receptor leads to receptor internalization, inhibition of cell cycle progression and antibody dependent 
cellular toxicity or eliciting the immune response. Herceptin induces normalization and regression of 
angiogenesis in HER-2 overexpressing breast cancer [46] and even blocks cleavage of HER2, which Int. J. Med. Sci. 2004 1(2): 101-115 
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generates a membrane-bound constitutively active truncated receptor. Rituximab is an anti CD20 
antibody, effective against Non Hodkins Lymphoma  [47]. 
EFGR is also overexpresed in many cancers especially in breast cancer. EGFR over amplification 
also leads to suppression of apoptosis. Proliferation, migration, stromal cell invasion and 
neovascularization. Important anti-EGFR monoclonal antibodies are C225 by Imclone and 2C4 by 
Genetech and Osidem by Mederex. C225 or cetuximab is targeted against EGFR/ Erb B1 while 2C4 is 
targeted against HER-2/ Erb B2 member of the EGFR family. Angiogenesis, the formation of new 
blood vessels to the tumor site is mainly induced and regulated by VEGF. Blocking angiogenesis is now 
considered to be a promising approach for anticancer therapy and the use of anti-VEGF MAb has 
demonstrated tumor suppression. 
Certain antigens are overexpressed in cancers. P12 antigen overexpression is associated with a 
wide range of cancer cell lines and tissues and antibody directed towards these antigens may serve as 
important contributors to cancer therapeutics as exemplified by the results of priliminary trials. MAb 
P12 reacts with the carbohydrate sequence present on high molecular weight glycoproteins. Oncologists 
are now interested in newer MAbs as promising agents for the treatment of cancer. 
5.5.  Hsp 90 and other novel strategies 
Heat shock proteins (Hsp-s) are ubiquitous proteins known for the maintenance of cellular 
homeostasis and are inducible under variety of stresses. Hsp-s are mainly involved in the proper folding 
of other proteins and hence referred to as molecular chaperons [48,49]. The accumulation of Hsp-s is 
seen in pathological conditions and tumors. Most kinases require molecular chaperons to maintain their 
activation competent conformation. Hsp-s interacts with and stabilizes various kinases  [50]. Chaperon 
based inhibitors other than interacting with protein kinases, prevent the associated chaperon(s) from 
maintaining the activation competent conformation of the kinase. The result being the proteosomal 
degradation of the misfolded kinases, thus diminishing the level of many kinases. The Hsp-s has an 
unique ATP binding site, including a Bergerat fold characteristic of bacterial gyrase, topoisomerases 
and histidine kinases. Thus the ATP binding site serves as a robust antitumor target for kinase related 
chaperone machinery. Important examples are Geldanamycin, Cisplatin, Novobiocin, Radicol and other 
purine based inhibitors. Geldanamycin affects ErbB2, EGF, v-Src, Raf-1 etc  [51,52]. 
5.6.  Antibody drug conjugate 
Frontline therapy being scarcely full proof, hence there is a resurgent trend towards 
immunotherapy. The efficacy of the antibodies that targets specific molecules expressed by tumor cells 
can be increased by attaching toxins to them  [53]. Existing immunotoxins are based on bacterial toxins 
like pseudomonas exotoxin, plant exotoxin like ricin or radio-nucleotides. The toxins are chemically 
conjugated to a specific ligand such as the variable domain of the heavy or light chain of the 
monoclonal antibody. Normal cells lacking the cancer specific antigens are not targeted by the targeted 
antibody  [54]. The most promising immunotoxin is the EGF fusion protein DAB389EGF, which is a 
fused EGF specific sequence and diphtheria toxin and have been found to be effective in EGFR over 
expressing breast tumor and non small cell lung cancer. The use of therapeutic antibody for the 
development of antibody-drug conjugate has been tried to improve the therapeutic potential e.g. 
Tositumomab by GlaxoSmithcline  [55], Anti-Tac(Fv)-PE38(LMB-2) against CD25, in B, T cell 
lymphoma and anti-B4-bR against CD19 in B-Non Hodgkins lymphoma [56]. As molecular studies of 
cancer have started revealing an increased epitope repertoire due to great strides in genomics and 
proteomics, the search for more effective Antibody-drug conjugate has got a spur in recent times [57]. 
5.7.  Antisense strategies and peptide drugs 
Antisense are small pieces of synthetic oligonucleotides that are designed to interact with the 
mRNA by Watson-Crick base pairing to block the transcription and thus translation of target proteins. 
Antisense oligodeoxynucleotides (ODN) targeting IGF-1R induces apoptosis in malignant melanoma 
and is also effective in breast cancer [58]. 
Protein–protein interaction is very important in cellular processes. Hence peptide and 
peptidomimetics that interfere with this interaction are important. Grb2 is an essential component in the 
Ras signaling pathway and it’s interaction with Sos is responsible for the down stream signaling 
process. Proline rich “Peptidimer” having two VPPVPPRRR sequence specifically recognizes Grb2 and Int. J. Med. Sci. 2004 1(2): 101-115 
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selectively blocks Grb2-Sos interaction an important step in EGFR over expressing cancers [31]. Small 
peptides mAZpTyr-(α-Me)pTyr-Asn-NH2 [58] and peptidomimetics like AHNP anti erbB2 are even 
known to inhibit unwanted tyrosine kinase dimerization by competing with target proteins thus the 
peptides or peptidomimetics acts as antagonist of receptor tyrosine kinase  [59,60].  
5.8.  Inhibitors of Angiogenesis 
Tumor cell transformation is a multistage process. An insitu tumor after a period of time abruptly 
sparks the formation of new blood vessels from the preexisting vasculature a process termed as 
angiogenesis or neovascularization. Tyrosine kinase plays an important role in this process [61]. This 
process though occurs normally during embryonic development, female reproductive cycle or wound 
healing is found as a crucial step in tumor transition from benign to malignant form, capable of 
spreading throughout the body [61, 62, 63]. 
VEGF (Flt-1) receptor tyrosine kinase mediated mitogenesis of human endothelial cells and 
growth of multiple tumor types is inhibited by SU5416 [64]. PD173074 is a potent inhibitor of FGFR1 
and also VEGFR2 [65]. PD98059 is an important inhibitor of MAPK cascade that lies downstream of 
Ras pathway and thus is effective in many tumors  [66]. Antiangiogenic drugs stops new vessels from 
forming around a tumor and break up the existing network of abnormal capillaries that feeds the 
cancerous mass, thus shrinks the tumor by limiting blood supply. Treatment of cancer faces the main 
fear of acquired drug resistance but antiangiogenic therapy does not induce acquired drug resistance and 
hence can prove valuable for long-term maintenance therapy  [67].  
Figure 6. Schematic structure of different approaches for tyrosine kinase inhibition 
 
6.  Mining the kinome to meet the future challenges 
Cancer arises by clonal proliferation from a cell, which builds up a series of mutations leading to 
abnormal signaling [68]. The Achilles’ heel lies in that the cancer cell depends highly on these 
oncogenic mutations and is said to be “oncogene addicted”  [69,70]. With over 500 kinases in the 
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human kinome and as many as 200-300 protein kinases mediating a large number of pathways in a cell 
at a particular time, selectivity becomes very important considering the cost of drug development. 
Hence strategies to move kinase drug discovery in a more rapid, comprehensive and efficient manner, 
including tyrosine kinase target validation, selectivity and drugability are the demand of time [71].  
Biochemical, cell based assay and screening methods for the through profiling of the kinase 
inhibitors using monoclonal antibody based multi-immunoblotting, fluorescent polarization assays, 
nonradioactive high throughput assays, 2-D NMR approaches should be exploited. Structure based drug 
design (SBDD) strategies depending on bioinformatics, computational approaches, mathematical 
models of tumor and normal tissue response, highthroughput X-ray crystallography and chemo-
genomic approaches can be used to advance molecules through the routine drug discovery process. The 
use of recent strides in RNA interferance (RNAi) appears to be a promising approach for silencing gene 
expression, thus elucidating genetics of human disease with emphasis into the biological role of the 
kinase signaling pathways [72,73]. The promising progress made by the drugs Gleevec, Iressa and 
Herceptin has brought to light the potential of new innovative genome based molecular therapeutics 
[74]           
7.  Conclusion 
The role of tyrosine kinase in the control of cellular growth and differentiation is central to all 
organisms and has been found to participate in human neoplastic diseases. Tyrosine kinase inhibitors 
and their potential in clinical application are well documented by dramatic examples like, Gleevec, 
Iressa and Herceptin. Several tyrosine kinase inhibitors are undergoing human trials and several are in 
the pipeline of drug discovery. The activities of these drugs are restricted to cancers with alterations in 
kinase targets, hence broad application of this treatment strategy are challenging. The quick selection of 
epidemiologically relevant, drugable tyrosine kinase targets coupled to efficient lead finding and 
optimization needs more intervention in the area of highthroughput cancer genome based molecular 
therapeutics. All these concerted effort may pave the silverlining to tailor made personalised cancer 
therapeutics.  
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Tables and Figures 
Table 1. Mechanism of oncogenic activation of tyrosine kinase 
Table 2. Protein kinase inhibitors in clinical trials 
Inhibitor Target  kinase(s)  Company  Cancer Status  Ref. 
Small molecule 
inhibitors 
        
STI-571  Abl, c-kit, PDGFR  Novartis  CML, GIST  launched   [39] 
ZD1839  EGFR  AstraZeneca  NSCLC, SCC  launched   [40] 
OSI-774  EGFR  OSI/Genetech  SCC, BC, LC  Phase III  [75] 
PKI-166  EGFR, Her-2  Novartis  general cancer  Phase II  [76] 
PTK-787  VEGFR  Novartis  CR cancer  Phase III  [77] 
SU5416  VEGFR  Sugen  solid tumor   Phase III   
Monoclonal antibody          
Herceptin Her-2/neu  Genetech  BC  FDA 
approved 
 [46] 
MDX-H210 Her-2/neu  Madarex  BC  Phase  I  [78] 
2C4  Her-2/neu  Genetech  BC, PC, OC  Phase II    - 
C225  EGFR  Imclone  Pan.C, BC, RenC  Phase III    - 
Antisense          
ISIS 3521  PKC-α  ISIS  NSCLC, BC, Pan.C  Phase II  [79] 
GEM 231  PKA  Hybridon  CR, Pan.C, LC  Phase I  [80] 
Immunotoxins          
Anti-Tac (Fv)-PE38   CD25  -  B, T cell leukemia  Phase I  [81] 
DAB389IL2  IL-2R  -         CTCL, HD, B-NHL  Phase III  [82] 
Hsp90 inhibitors          
Geldanamycin  Hsp90  Conforma. Inc.  Thyroid cancer  Phase I  [83] 
17-AAG  Hsp90  -                  BC Phase I  Phase I  [84] 
BC- Breast cancer, LC- Lung cancer, NSCLC- Non small cell lung cancer, SSC- squamous cell carcinoma, CR- 
Colorectal cancer, CML- Chronic myeloid leukemia, GIST- Gastrointestinial stromal tumor, CTCL-Cutaneous T 
cell lymphoma, NHL- Non Hodgkins lymphoma, HD- Hodgkins disease, Pan.C – Pancreatic cancer, Ren.C- 
Renal cancer, KHK- Kyowa Hakko Kogyo Ltd. 
 
Gene Mutation  Disease 
EGFRvIII Extracellular  domain  Glioblastoma, Ovarian tumor, 
Non small cell lung carcinoma 
FGFR3 Extracellular  domain  Multiple  myeloma 
BCR-ABL  Translocation 
t(9:22) 
Chronic myeloid leukemia 
Acute lymphocytic leukemia 
TEl-ABL  Translocation 
t(9:12)  Acute lymphocytic leukemia 
TEL-PDGF  Translocation 
t(5:12)  Chronic myeloid monocytic leukemia 
EGFR and 
EGF, TGFα 
Autocrine-paracrine loop 
Non small cell lung carcinoma 
Bladder cancer 
Glioblastoma multiforme 
PDGFR and 
PDGF  Autocrine-paracrine loop  Glioma 
IGFR and 
IGF I and II  Autocrine-paracrine loop  Breast cancer 